Radezolid is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals

Rib-X Pharmaceuticals

Rib-X Pharmaceuticals, founded in 2000, is a privately-held biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut...

, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

External links

• Radezolid at Rib-X Pharmaceuticals